Filtered By:
Drug: Eloxatin

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 66 results found since Jan 2013.

siRNA-induced CD44 knockdown suppresses the proliferation and invasion of colorectal cancer stem cells through inhibiting epithelial-mesenchymal transition
J Cell Mol Med. 2022 Mar 1. doi: 10.1111/jcmm.17221. Online ahead of print.ABSTRACTCD44 has shown prognostic values and promising therapeutic potential in multiple human cancers; however, the effects of CD44 silencing on biological behaviors of cancer stem cells (CSCs) have not been fully understood in colorectal cancer. To examine the contribution of siRNA-induced knockdown of CD44 to the biological features of colorectal CSCs, colorectal CSCs HCT116-CSCs were generated, and CD44 was knocked down in HCT116-CSCs using siRNA. The proliferation, migration and invasion of HCT116-CSCs were measured, and apoptosis and cell-cycl...
Source: J Cell Mol Med - March 1, 2022 Category: Molecular Biology Authors: Weiyan Zou Yi Zhang Guangfu Bai Jialu Zhuang Lin Wei Zishu Wang Meiqun Sun Junbin Wang Source Type: research

Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer
Chemotherapy resistance represents a formidable obstacle in advanced or metastatic colorectal cancer (CRC) patients. It is reported that ATPase copper transporting alpha (ATP7A) plays an important role in chemotherapy resistance in CRC. Here, we identified ATP7A as a potentially key gene of OXA resistance in CRC. The patients with higher expression of ATP7A tended to have platinum drug resistance. While the lower expression of ATP7A by siRNA knockdown resulted in enhancement of OXA sensitivity and increased OXA-induced apoptosis. Further, we demonstrated a novel and safe strategy to increase CRC chemosensitivity by deliver...
Source: Frontiers in Oncology - February 21, 2022 Category: Cancer & Oncology Source Type: research

ASAP Functionalized LbL Film for Localized Delivery of STAT3 siRNA and Oxaliplatin Combination to Treat Colon Cancer
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.1c22166
Source: ACS Applied Materials and Interfaces - February 16, 2022 Category: Materials Science Authors: Leela Sai Lokesh Janardhanam, Sony Priyanka Bandi, and Venkata Vamsi Krishna Venuganti Source Type: research

The Antitumor Effect of TPD52L2 Silencing on Oxaliplatin-Resistant Gastric Carcinoma Is Related to Endoplasmic Reticulum Stress < em > In Vitro < /em >
Evid Based Complement Alternat Med. 2022 Jan 18;2022:4451178. doi: 10.1155/2022/4451178. eCollection 2022.ABSTRACTTumor protein D52-like 2 or simply TPD52L2 belongs to the TPD52 family which has been implicated in a variety of human carcinomas. However, the TPD52L2 function in the gastric carcinoma oxaliplatin (OXA) resistance remains elusive. The main objective of this study is to evaluate the TPD52L2 effect in OXA-resistant gastric carcinoma cells in vitro. Oxaliplatin-resistant gastric carcinoma cells were generated in MGC-803 and SGC-7901 cells. siRNA-mediated knockdown of TPD52L2 was investigated in OXA-resistant MGC-...
Source: Evidence-based Complementary and Alternative Medicine - January 28, 2022 Category: Complementary Medicine Authors: Yu Zhang Dejun Yang Ziran Wei Xin Zhang Zunqi Hu Hongbing Fu Jiapeng Xu Weijun Wang Source Type: research

ZEB1 Induces Ddr1  Promoter Hypermethylation and Contributes to the Chronic Pain in Spinal Cord in Rats Following Oxaliplatin Treatment
In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.PMID:34032956 | DOI:10.1007/s11064-021-03355-5
Source: Neurochemical Research - May 25, 2021 Category: Neuroscience Authors: Yi-Ying Chen Kai-Sheng Jiang Xiao-Hui Bai Meng Liu Su-Yan Lin Ting Xu Jia-You Wei Dai Li Yuan-Chang Xiong Wen-Jun Xin Zhen-Yu Li Source Type: research

Cancers, Vol. 13, Pages 2019: Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14ARF-Mediated Sustained p53 Activation
ristmann Senescence is an important consequence of cytostatic drug-based tumor therapy. Here we analyzed to which degree the anticancer drug oxaliplatin induces cell death, cell cycle arrest, and senescence in colorectal cancer (CRC) cells and elucidated the role of p53. Oxaliplatin treatment resulted in the G2-phase arrest in all CRC lines tested (HCT116p53+/+, HCT116p53−/−, LoVo, SW48 and SW480). Immunoblot analysis showed that within the p53-competent lines p53 and p21CIP1 are activated at early times upon oxaliplatin treatment. However, at later times, only LoVo cells showed sustained activation of the p53/p21C...
Source: Cancers - April 22, 2021 Category: Cancer & Oncology Authors: Maja T. Tomicic Franziska Kr ämer Alexandra Nguyen Christian Schwarzenbach Markus Christmann Tags: Article Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 16, 2021 Category: Drugs & Pharmacology Authors: Zahra Asadzadeh Behzad Mansoori Ali Mohammadi Tohid Kazemi Ahad Mokhtarzadeh Dariush Shanehbandi Nima Hemmat Afshin Derakhshani Oronzo Brunetti Sahar Safaei Marjan Aghajani Souzan Najafi Nicola Silvestris Behzad Baradaran Source Type: research

The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy.
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 13, 2021 Category: Drugs & Pharmacology Authors: Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, Aghajani M, Najafi S, Silvestris N, Baradaran B Tags: Biomed Pharmacother Source Type: research

Cancers, Vol. 13, Pages 724: SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells
In this study, we performed a stable isotope labelling by amino acids in cell culture (SILAC)-based quantitative proteomics analysis of oxaliplatin-resistant and sensitive pancreatic cancer PANC-1 cells. We identified 107 proteins whose expression levels changed (thresholds of 2-fold changes and p-value ≤ 0.05) between oxaliplatin-resistant and sensitive cells, which were involved in multiple biological processes, including DNA repair, cell cycle process, and type I interferon signaling pathway. Notably, myristoylated alanine-rich C-kinase substrate (MARCKS) and Wntless homolog protein (WLS) were upregulated in oxaliplat...
Source: Cancers - February 10, 2021 Category: Cancer & Oncology Authors: Young Eun Kim Eun-Kyung Kim Min-Jeong Song Tae-Young Kim Ho Hee Jang Dukjin Kang Tags: Article Source Type: research

OSI-027 alleviates oxaliplatin chemoresistance in gastric cancer cells by suppressing P-gp induction.
Abstract Gastric cancer is one of the most common malignancies worldwide and the third leading cause of cancer-related death. In the present study, we investigated the potential activity of OSI-027, a potent and selective mammalian target of rapamycin complex 1/2 (mTOR1/2) dual inhibitor, alone or in combination with oxaliplatin against gastric cancer cells in vitro. Cell counting kit-8 assays and EdU staining were performed to examine the proliferation of cancer cells. Cell cycle and apoptosis were detected by flow cytometry. Western blot was used to detect the elements of the mTOR pathway and Pgp in gastric canc...
Source: Current Molecular Medicine - November 19, 2020 Category: Molecular Biology Authors: Xu E, Zhu H, Wang F, Miao J, Du S, Zheng C, Wang X, Li Z, Xu F, Xia X, Guan W Tags: Curr Mol Med Source Type: research

CD44 expression enhances chemoresistance and implies occult micrometastases after conversion hepatectomy for initially unresectable colorectal liver metastases.
CONCLUSIONS: CD44 enhances chemoresistance in response to anti-cancer drugs (fluorouracil and oxaliplatin) in colon cancer cells. CD44 expression in liver metastases after chemotherapy implies the presence of occult micrometastases and is a worse prognostic factor in patients with conversion hepatectomy for initially unresectable colorectal liver metastases. PMID: 33042471 [PubMed]
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research

WASF3 Knockdown Sensitizes Gastric Cancer Cells to Oxaliplatin by Inhibiting ATG12-Mediated Autophagy.
CONCLUSIONS: Our analysis demonstrates WASF3 targeting is a new potential therapeutic strategy for gastric cancer. PMID: 32359534 [PubMed - in process]
Source: The American Journal of the Medical Sciences - April 30, 2020 Category: General Medicine Authors: Nie Y, Liang X, Liu S, Guo F, Fang N, Zhou F Tags: Am J Med Sci Source Type: research